Gain Therapeutics, Inc.

Contributing Author

Recent Articles by Gain Therapeutics, Inc.

Jun-29	Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease GANX +13.14% GlobeNewswire
Jun-10	Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit GANX GlobeNewswire
May-26	Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026 GANX GlobeNewswire
May-11	Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update GANX GlobeNewswire
Apr-24	Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026 GANX GlobeNewswire
Mar-26	Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update GANX GlobeNewswire
Mar-19	Gain Therapeutics to Present at the 38th Annual ROTH Conference GANX GlobeNewswire
Mar-18	Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 GANX -25.57% GlobeNewswire
Mar-12	Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update GANX GlobeNewswire
Feb-19	Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference GANX GlobeNewswire
Jan-07	Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week GANX -5.49% GlobeNewswire
Jan-06	Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 GANX -14.14% GlobeNewswire
Dec-18	Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease GANX -44.44% GANX +27.78% GlobeNewswire
Dec-18	Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease GANX -44.44% GlobeNewswire
Nov-20	Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025 GANX GlobeNewswire
Nov-12	Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update GANX +10.07% GlobeNewswire
Oct-30	Gain Therapeutics to Present at Neuroscience 2025 GANX GlobeNewswire
Oct-16	Gain Therapeutics to Attend the 2025 Maxim Growth Summit GANX GlobeNewswire
Oct-09	Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease GANX GlobeNewswire
Oct-06	Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders GANX +15.62% GlobeNewswire
Sep-23	Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025 GANX GlobeNewswire
Sep-18	Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease GANX +7.59% GlobeNewswire
Sep-04	Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation GANX -9.38% GlobeNewswire
Aug-12	Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update GANX GlobeNewswire
Jul-24	Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference GANX GlobeNewswire
Jul-16	Gain Therapeutics Announces Pricing of $7.0 Million Public Offering GANX GlobeNewswire
Jul-15	Gain Therapeutics Announces Proposed Public Offering GANX -8.60% GlobeNewswire
Jun-30	Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation GANX -8.63% GANX -12.78% GlobeNewswire
Jun-10	Gain Therapeutics to Participate in Upcoming Investor Conferences GANX GlobeNewswire
May-29	Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting GANX GlobeNewswire
May-14	Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update GANX GlobeNewswire
May-12	Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders GANX GlobeNewswire

Gain Therapeutics, Inc.

Recent Articles by Gain Therapeutics, Inc.

Upgrade your Finviz experience